Expanding Overseas Sales, Primarily in North America and Asia-Pacific
First written in FY2022-Q2. 5 of 13 entries say "Advanced", first in FY2022-Q3. Latest entry: FY2026.
PHC Holdings moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2026: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The Group's revenue by region was Japan ¥154,577 million, Europe ¥90,995 million, North America ¥75,032 million and Other ¥43,797 million.」
Overseas sales continued to account for more than half of total revenue, but revenue increased in Europe and declined in North America, with regional growth differing. - FY2026-H1ReframedAnnual report
「Excluding foreign exchange effects, pathology business revenue was in line with the previous corresponding period. Revenue declined in the Americas due to the ongoing impact of sluggish demand for instruments, but increased in Europe, where sales of glass products and consumables remained solid and a large digital pathology product order was secured in the first quarter of the current consolidated fiscal period, and in the Asia-Pacific region, where revenue grew as the product portfolio of locally manufactured products was expanded, including the start of digital pathology product manufacturing in China.」
Overseas sales did not expand uniformly: consumables, large-scale projects and locally manufactured products contributed in Europe and Asia-Pacific, while equipment demand remained stagnant in the Americas. - FY2025RestatedAnnual report
「The Group's revenue by region for the fiscal year ended March 2025 was Japan 43.2%, Europe 23.3%, North America 21.9% and Other 11.7%.」
Overseas sales continued to account for more than half of total revenue. Revenue increased in Japan and North America but declined in Europe, with trends differing by region. - FY2025-H1ReframedAnnual report
「Although the Pathology business recorded lower revenue due to sluggish equipment sales amid weak market conditions and lower demand in Asia-Pacific, mainly China, revenue increased overall owing to the favorable impact of foreign exchange movements and strong consumables sales in the Americas and Europe.」
The overseas business did not expand uniformly: demand declined in Asia-Pacific, including China, while consumables sales in the Americas and Europe and foreign exchange movements supported revenue growth. - FY2024RestatedAnnual report
「The Group's revenue by region for the fiscal year ended March 2024 was Japan 42.5%, Europe 24.3%, North America 21.3% and Other 11.9%.」
It reconfirms that overseas sales account for more than half of revenue. Europe recorded lower revenue, North America a slight increase and other regions higher revenue, with trends differing by region. - FY2024-Q3ReframedAnnual report
「The increase in revenue in the Pathology business was primarily attributable to the favorable impact of foreign exchange movements, the impact of product shortages caused by COVID-19 during the first quarter of the prior fiscal year, the effects of the M&A conducted in July of the prior year, and the effects of product price revisions. By region, revenue increased in all regions, partly due to favorable foreign exchange movements, while Europe and Asia-Pacific recorded significant growth mainly because of the aforementioned product shortages in the prior year.」
While overseas sales growth in the Pathology business was seen in all regions, including Europe and Asia-Pacific, the Biomedica business recorded lower revenue in the Americas and Europe, indicating that the drivers of regional growth differ by business. - FY2024-Q2RestatedAnnual report
「By region, revenue increased in Europe and Asia-Pacific and rose slightly in the Americas.」
In the Pathology business, revenue growth continued in Europe and Asia-Pacific, while the Americas also recorded a slight increase. - FY2024-Q1AdvancedAnnual report
「In the Pathology business, revenue increased year on year, primarily because equipment sales increased in Europe and Asia-Pacific, in addition to the favorable impact of foreign exchange movements, the effects of M&A and product price revisions, compared with the prior-year period, which was affected by product shortages caused by COVID-19 lockdowns in China.」
Revenue from Diagnostics and Life Sciences increased 4.8% year on year, driven by higher equipment sales in Europe and Asia-Pacific. The Company also reported restrained capital investment in the Americas due to the economic slowdown. - FY2023-Q3AdvancedAnnual report
「In the Americas, the Company won numerous new construction and expansion projects for life sciences research facilities, primarily for pharmaceutical and biotech companies. In Europe, sales to general-demand markets increased significantly, while demand for ultra-low-temperature freezers at mRNA vaccine manufacturing sites remained firm. Together with the favorable impact of foreign exchange movements, these factors resulted in significant revenue growth in both regions.」
Revenue from Diagnostics and Life Sciences increased 17.6% year on year, driven by new construction and expansion projects for research facilities in the Americas and general-market sales and demand for ultra-low-temperature freezers in Europe. - FY2023-Q2AdvancedAnnual report
「Particularly in the Americas, the Company won numerous new construction and expansion projects for life sciences research facilities, and revenue increased with the benefit of foreign exchange movements.」
The Company won numerous new construction and expansion projects for research facilities in the Americas, and revenue from Diagnostics and Life Sciences increased 11.9% year on year. - FY2023-Q1AdvancedAnnual report
「Particularly in the Americas, the Company won numerous new construction and expansion projects for life sciences research facilities, and revenue increased with the benefit of foreign exchange movements.」
The Company won numerous new construction and expansion projects for research facilities in the Americas, and revenue from Diagnostics and Life Sciences increased 6.7% year on year. - FY2022-Q3AdvancedAnnual report
「In the Pathology business, routine hospital examinations, which had been deferred due to the spread of COVID-19, began to recover. Although some shipments in the Americas and Europe were affected by supply chain issues, revenue increased year on year.」
Reports year-on-year revenue growth in the Americas and Europe despite supply chain constraints, against a backdrop of recovering routine hospital examinations. - FY2022-Q2First statedAnnual report
「By region, the business recorded significant revenue growth in North America, up 26.5% year on year, and in Asia-Pacific, driven by China, up 19.6%.」
Reports increased revenue in the Diagnostics and Life Sciences business in North America and the Asia-Pacific region, including China.